Compare TMP & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TMP | SDGR |
|---|---|---|
| Founded | 1836 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1996 | 2020 |
| Metric | TMP | SDGR |
|---|---|---|
| Price | $94.54 | $16.88 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $87.00 | $21.00 |
| AVG Volume (30 Days) | 85.0K | ★ 1.5M |
| Earning Date | 04-24-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | ★ 126.16 | 45.14 |
| EPS | ★ 1.82 | N/A |
| Revenue | $75,742,000.00 | ★ $255,869,000.00 |
| Revenue This Year | N/A | $0.76 |
| Revenue Next Year | $7.94 | $4.60 |
| P/E Ratio | $51.95 | ★ N/A |
| Revenue Growth | N/A | ★ 23.29 |
| 52 Week Low | $61.87 | $10.95 |
| 52 Week High | $97.12 | $23.75 |
| Indicator | TMP | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 64.27 | 63.87 |
| Support Level | $81.09 | $16.84 |
| Resistance Level | N/A | $19.15 |
| Average True Range (ATR) | 2.04 | 1.06 |
| MACD | 0.29 | 0.09 |
| Stochastic Oscillator | 74.63 | 74.07 |
Tompkins Financial Corp is a Financial Holding Company. The company manages its operations through two business segments, consisting of banking and wealth management. It offers various products and services, including commercial and consumer banking, leasing, trust and investment management, financial planning and wealth management, and insurance. Wealth management activities include the results of the company's trust, financial planning, and wealth management services. The company generates the majority of its revenue from the Banking segment.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.